North America Molecular Infectious Disease Testing Market Outlook (2025-2035)
The North America Molecular Infectious Disease Testing Market is characterized by rapid advancements in molecular diagnostics, offering precise, timely identification of pathogens. Leveraging technologies such as PCR, isothermal nucleic acid amplification, and next-generation sequencing, the market enables effective detection and management of various infectious diseases including respiratory illnesses, hepatitis, HIV, and hospital-acquired infections. This market comprises a broad spectrum of applications spanning hospitals, diagnostic laboratories, research institutes, point-of-care testing, and retail pharmacies. The sector is witnessing substantial investment, fierce competition, and technological innovation, which drive accessibility and accuracy across the region, particularly in the US, Canada, and Mexico.
Latest Market Dynamics
Key Drivers
Rising incidence of infectious diseases and hospital-acquired infections, fueling demand for rapid diagnostics. For example,
expanded its Alinity m molecular testing platform in 2024 to cover more infectious agents.
Advancements in molecular testing technologies, particularly automation and multiplex PCR systems, leading to enhanced throughput and accuracy. Roche Diagnostics launched its new Cobas Pro integrated platform in June 2024 to streamline workflow in laboratories.
Key Trends
Integration of point-of-care molecular testing for quick disease identification outside traditional labs. In 2024, Cepheid (Danaher Corporation) released expanded testing panels for respiratory viruses at the point-of-care.
Adoption of next-generation sequencing for high-throughput infectious disease research and surveillance, as seen with Thermo Fisher Scientific launching new NGS panels in early 2024 for comprehensive pathogen detection.
Key Opportunities
Expanding test menu for respiratory and multi-pathogen panels, especially relevant after the COVID-19 pandemic. Hologic Inc. launched its Panther Fusion module for broad respiratory panel testing in 2024.
Growing partnerships between diagnostic vendors and healthcare providers to improve test access and adoption. In 2024, Siemens Healthineers collaborated with major US hospital networks to deploy molecular testing platforms.
Key Challenges
Complex regulatory requirements, particularly for novel molecular assays, may delay market entry. Companies like Qiagen faced regulatory review extensions for new NAAT products in Q3 2024.
High cost of advanced molecular testing platforms and reagents, challenging adoption in mid-sized and smaller labs. Bio-Rad Laboratories reported market uptake constraints among medium-sized US labs in its Q2 2024 financial update.
Key Restraints
Limited technical expertise and workforce shortages in molecular diagnostics, particularly outside major urban areas. GenMark Diagnostics noted this in its 2024 customer survey across North America.
Stringent reimbursement policies impacting test affordability and adoption, as highlighted by Grifols in its June 2024 market access report.
In 2025, Polymerase Chain Reaction (PCR) dominates the North America Molecular Infectious Disease Testing Market, capturing the largest market share at 47%. PCR's prominence is attributed to its accuracy, broad application range, and ongoing technological refinement. Isothermal Nucleic Acid Amplification follows with 21%, benefiting from its rapid turnaround and ease of use in point-of-care settings. Next-Generation Sequencing accounts for 15%, reflecting its rising role for detailed pathogen analysis and outbreak surveillance. DNA Microarray, Hybridization, and Others collectively make up the remaining 17%. The dominance of PCR and rapid amplification technologies showcase the region's preference for quick, reliable diagnostics as the demand for advanced molecular tools escalates.
In 2025, Respiratory Diseases represent the largest application segment in the North America market, accounting for 38% of total demand. The continued burden of respiratory pathogens post-pandemic drives sustained demand for molecular assays in this area. Hospital-Acquired Infections garner 22%, reflecting hospitals’ emphasis on infection surveillance and prevention. HIV and Hepatitis testing together constitute 25% (HIV at 14% and Hepatitis at 11%) as molecular assays remain essential tools for management and monitoring of these chronic infections. Gastrointestinal Diseases capture 9%, with Others comprising the remaining 6%. Overall, the dominance of respiratory and hospital infection applications underlines the market’s focus on early detection and public health response.
The North America Molecular Infectious Disease Testing Market is projected to grow from 5630 million USD in 2020 to 10450 million USD by 2035. The years 2020-2025 witness sharp growth due to increased demand for respiratory and multi-pathogen testing triggered by the COVID-19 pandemic. Post-2025, the market stabilizes yet maintains a robust upward trajectory, propelled by technological innovations, expansion in testing menus, and growing adoption across diverse healthcare settings. Ongoing investments in automation and next-generation technologies further fuel revenue expansion through the forecast period.
Year-on-year (YOY) growth for the North America Molecular Infectious Disease Testing Market peaked at 11.8% from 2020 to 2021 due to pandemic-driven demand. Growth then moderates to 6.2% between 2025 and 2030, and further to 4.5% from 2030 to 2035. This reflects the normalization post-pandemic, a maturing diagnostics market, and strengthened adoption of routine molecular screening protocols in clinical settings. Steady YOY increases signal sustained sector investment and expanding diagnostic access across the region.
The United States dominates the North America Molecular Infectious Disease Testing Market in 2025 with a commanding 79% share, attributed to advanced healthcare infrastructure, higher testing volumes, and a strong presence of key market players. Canada follows with a 13% share, reflecting growing investment in diagnostic technologies and national health system initiatives. Mexico holds 8%, stimulated by improved healthcare system funding and expanding laboratory capabilities. The regional distribution underscores the US as the principal innovator and adopter, with Canada and Mexico contributing steadily rising demand.
Roche Diagnostics leads with 23% share in the North America Molecular Infectious Disease Testing Market, owing to its robust molecular diagnostics portfolio. Abbott Laboratories holds the second largest share at 17% due to widespread adoption of its Alinity and m2000 platforms, followed by Hologic Inc. at 14%, benefiting from its Panther Fusion system. Becton, Dickinson and Company, Thermo Fisher Scientific, Cepheid (Danaher), and others jointly make up the remaining 46%. This distribution reflects a highly competitive landscape dominated by established multinational players supporting broad market penetration.
Hospitals form the largest buyer segment in 2025, securing 52% of the North America molecular infectious disease testing market due to high-volume routine and emergency molecular testing. Diagnostic Laboratories hold a 28% share, driven by specialized and reference testing services. Point-of-Care Testing accounts for 12% as decentralized testing gains traction, while Research Institutes and Other buyers (including retail pharmacies) represent the remaining 8%. The distribution highlights the central role of hospitals and labs, with growing opportunities in decentralized and community-based care.
June 2024: Roche Diagnostics launched its Cobas Pro integrated platform in North America, enhancing laboratory workflow and throughput for molecular testing.
July 2024: Cepheid (Danaher Corporation) received FDA clearance for expanded respiratory virus panel including SARS-CoV-2 and RSV.
August 2024: Thermo Fisher Scientific introduced new NGS panels targeted for rapid, high-throughput infectious disease surveillance across hospital networks.
September 2024: Siemens Healthineers announced strategic collaborations with US hospital systems for deployment of advanced molecular diagnostics solutions.
October 2024: Abbott Laboratories expanded distribution of its Alinity m platform to cover additional infectious disease assays in the United States and Canada.
Frequently Asked Questions
About the Author
Mike
Lead Industry Analyst
Mike is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Mike brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Mike has helped organizations translate data into actionable growth strategies.
